However, there is no indication for pharmacologic replacement e. Patients can be treated with supportive care by intravenous fluids and antiemetics if necessary. If marked psychiatric symptoms persist longer than one or more weeks after discontinuation, the patient should be evaluated carefully to determine whether he or she has a co-occurring primary psychiatric disorder, which then should be treated with specific therapy [ 67 ]. Treatment of prolonged anxiety, depression, or psychosis is the same as when these conditions are not associated with recent designer drug use.
For a significant number of patients, the high level of illness severity warrants admission to critical care. Intoxicated patients should be placed initially on continuous cardiac monitoring with pulse oximetry and frequent neurological assessments [ 63 ]. Adequate administration of intravenous fluids is encouraged to assure good urine output, as these patients often are dehydrated [ 63 ]. Fluid administration in the presence of rhabdomyolysis can help prevent acute renal failure.
Intensive monitoring allows for early detection and intervention for serious consequences, such as myocardial infarction. Patients may present with concurrent ingestion of drugs with different pharmacological profiles, including both stimulant and depressant drugs.
Clinicians should be alert for an unexpected response to a therapeutic intervention or to a change in patient presentation as one type of designer drug wears off and ongoing intoxication with another class of designer drug is revealed.
This may require some flexibility in treatment due to changes in mental or cardiovascular status. Hospitalization for the adverse effects of designer drugs affords an excellent opportunity teachable moment for advising patients to decrease their substance use and for engaging them in treatment [ 68 ].
Health-care provider awareness and patient education are cornerstones of public health initiatives [ 2 ] to confront new challenges presented by designer drugs.
Simple admonitions to stop are sometimes helpful if the diagnosis is made early, but in most cases are insufficient [ 69 ]. Providing appropriate, accurate information about the potential risks of designer drugs and encouraging healthy choices can help patients make the best informed decision about changing behavior.
Physicians should involve the patient proactively in the process of problem-solving, while reminding the patient of responsibility for all actions. The responsibility of the practitioner is to motivate the patient to seek recovery from designer drug use instead of blaming the patient for being unmotivated to change [ 69 ]. Accurate information about the relative risks and unknown harms of these products helps a patient make an informed choice about continuing to use particular products, to make a quit attempt, or to seek more specific addiction treatment.
Although prospective treatment data are limited, once a designer drug use disorder diagnosis is made, acute and long-term treatment is likely necessary [ 70 ]. Recovery from SUD in general is possible, and those who are treated have less disability than those who remain untreated [ 71 ].
Long-term treatment of designer drug use disorders likely involves similar components to that of other types of addiction treatment, including behavioral components, such as individual and group counseling with cognitive-behavioral therapy, motivational enhancement therapy, and Step self-help group facilitation.
Family members should be considered as part of the treatment program, in particular when treating adolescents or young adults. Unfortunately, pharmacologic treatment data to guide management of those with designer drug use disorders are unavailable. Patients identified with SUD in the ED or hospital inpatient setting should be provided with information linking them to local community addiction treatment resources.
In the United States, physicians certified in the treatment of addictive disorders can be found through the American Society of Addiction Medicine www. Treatment of designer drug SUD is challenging for several reasons. Designer drugs consist of several different classes of substances, which vary in their psychological and physiological effects. Treatment is often difficult due to the young age of most users and the possibility of concurrent polysubstance use.
The pattern of use is usually intermittent in social settings, so it may be perceived as less of a problem. Clinicians should be knowledgeable of and prepared to provide treatment for very different combinations, such as what occurs with club drug use [ 72 ]. A treatment environment with a supportive structure can be helpful. Addiction treatment is cost effective [ 73 ], and even multiple episodes of treatment are worthwhile.
It can be very rewarding for any health-care practitioner to assist a patient who was impaired by addiction return to normal functioning in society. Bath salts, SC, and 25I-NBOMe are relatively new designer drugs that continue to remain popular drugs of abuse, especially among young adults. Though chemically different, they are similar in that they are groups of synthetic analogs that continue to change in attempts to avoid legal issues and detection on drug tests.
They are also similar in that adverse reactions are common, especially clinically significant psychotic reactions.
Detection of these drugs with urine tests is challenging, so clinicians should consider designer drug use in young adults with agitation and psychosis. Treatment is primarily supportive, and benzodiazepines may be beneficial. When those who use designer drugs come into contact with the health-care system, it is important for clinicians to provide linkage to additional, specific treatment for the substance use disorder.
Drug Test Anal. J Emerg Med. Article PubMed Google Scholar. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. The toxicology investigators consortium case registry—the experience. J Med Toxicol. Mephedrone: use, subjective effects and health risks. Mephedrone, new kid for the chop? Clin Toxicol Phila.
A web-based survey on mephedrone. Drug Alcohol Depend. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. Google Scholar. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus. Camp NE. Synthetic cannabinoids. J Emerg Nurs. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample.
Drugs for youth via internet and the example of mephedrone. Toxicol Lett. Spice, bath salts, and the U. Mil Med. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. J Addict Med. Clinical toxicology of newer recreational drugs. Instability of the ecstasy market and a new kid on the block: mephedrone.
J Psychopharmacol. A harmless high? In Addictions: A Comprehensive Guidebook. Stimulants: amphetamines and cocaine. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review.
Gunderson EW. Synthetic cannabinoids: a new frontier of designer drugs. Ann Inter Med. Am J Addict. J Mass Spectrom. Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes.
Schizophr Res. Dtsch Arztebl Int. A survey study to characterize use of Spice products synthetic cannabinoids. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
J Pediatr Health Care. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Myocardial infarction associated with use of the synthetic cannabinoid K2. Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs.
Front Behav Neurosci. Evaluation of a vaporizing device Volcano for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. Spice drugs as a new trend: mode of action, identification and legislation. Drug Enforcement Administration, U. Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I.
Final Order. Fed Regist. Bioorg Med Chem. Article Google Scholar. We use cookies and other tracking technologies to improve your browsing experience on our site, show personalized content and targeted ads, analyze site traffic, and understand where our audiences come from.
To learn more or opt-out, read our Cookie Policy. On a July day a little over a year ago, over 30 people collapsed on a street in Brooklyn. They lay on the ground, vomiting down their shirts, twitching and blank-faced. Some, half-naked, made jerking movements with their arms, eyes rolled back. Others groaned and clutched onto fire hydrants to try to stay upright. Witnesses said the scene was like The Walking Dead. Eighteen people were sent to the hospital by ambulance.
The situation had all the signs of a drug overdose, and so doctors ordered the usual tests: blood count, urine analysis, heart rate monitoring. The first patient tested was a year-old man who was slow to respond, but otherwise showed few clear signs of trauma.
Heart sounds: normal. Blood count: normal. His lungs were clear and there were no major neurological problems, no excessive sweating or skin lesions. He tested negative for opiates, cocaine, amphetamines.
Nothing came up. They knew who to call to get a second opinion. They packed blood and urine samples on dry ice and shipped them to a small lab 3, miles away in San Francisco, run by toxicologist Roy Gerona. If anyone in the country could figure out what was in 24 Karat Gold, it would be him. Forty years ago, drugs had easy names: cocaine, meth, heroin.
Designer drugs are volatile. That year, according to the United Nations Office on Drug and Crime , there were about of these substances reported; six years later, there were nearly One of the most prominent categories of designer drugs are those intended to mimic marijuana, called synthetic cannabinoids.
Marijuana, or cannabis, is widely considered one of the safest drugs, but synthetic cannabinoids are some of the most dangerous synthetic drugs. The Global Drug Survey GDS found that last year, for the fourth year running, the risk of seeking emergency medical treatment was higher after using synthetic weed than for any other drug. When you smoke a regular joint, a chemical called tetrahydrocannabinol THC travels through your blood. What is N-bomb? Effects of N-bomb. N-bomb: A Short History.
The Truth About Drugs. Synthetic drugs are created using man-made chemicals rather than natural ingredients. Study by Recreational Drug European Network, How much do you really know about synthetic drugs?
Contact Us. Start Free E-Courses. Take the Quiz. Download Booklets. Law Enforcement. Sign the Drug-Free Pledge. Start an Online Class. Join a Team. Order Bulk Materials. Foundation for a Drug-Free World materials are in use by tens of thousands of schools and over law enforcement agencies across the globe.
0コメント